Press "Enter" to skip to content

FDA declines to approve reformulated Mallinckrodt opioid

The treatment is a reformulated version of Mallinckrodt’s commonly abused painkiller Roxicodone, intended to make the drug less desirable and more difficult to be abused by snorting or injecting.

Original source:

Also Read:   2 major pharma companies announce to co-develop potential COVID 19 vaccine